 Connection
Thomas Campbell to Ritonavir
This is a "connection" page, showing publications Thomas Campbell has written about Ritonavir.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.044 |
|
|
|
-
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013 Sep; 208(6):884-91.
Score: 0.024
-
Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|